We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Late skin fibrosis in systemic sclerosis: a study from the EUSTAR cohort.
- Authors
Hughes, Michael; Huang, Suiyuan; Alegre-Sancho, Juan Jose; Carreira, Patricia E; Engelhart, Merete; Hachulla, Eric; Henes, Joerg; Kerzberg, Eduardo; Pozzi, Maria Rosa; Riemekasten, Gabriela; Smith, Vanessa; Szücs, Gabriella; Vanthuyne, Marie; Zanatta, Elisabetta; Distler, Oliver; Gabrielli, Armando G; Hoffmann-Vold, Anna-Maria; Steen, Virginia D; Khanna, Dinesh; Collaborators, EUSTAR
- Abstract
Objectives The early trajectory of skin fibrosis provides insights into the disease course of systemic sclerosis (SSc) including mortality; however, little is known about late skin fibrosis. The aims of our study were to ascertain the prevalence and characteristics of late skin fibrosis in SSc. Methods We developed and tested three conceptual scenarios of late (>5 years after first non-RP feature) skin fibrosis including new worsening of skin disease, and failure to improve after worsening within 5-year window. We defined skin worsening as change in modified Rodnan skin score (mRSS) ≥5 units or ≥25%. Using strict inclusion criteria including complete mRSS, we identified 1,043 (out of 19 115) patients within the EUSTAR database for our analysis. We further restricted analysis within 887 (out of 1043) patients who had lcSSc or dcSSc at baseline. Results One-fifth of patients among the whole cohort (n = 208/1043, 19.9%) experienced mRSS worsening, including in patients with lcSSc or dcSSc at baseline (n = 193/887, 21.8%). This was largely due to new skin worsening after the 5-year window or failure to improve with worsening within the 5-year window. Patients with lower baseline mRSS and lcSSc were more likely to develop late skin fibrosis. Anti-Scl-70 was associated with progression from baseline lcSSc to dcSSc, and anticentromere was protective. Conclusions Late skin fibrosis is not uncommon in SSc. We have identified different patterns relevant to clinical practice and trial design. Late skin fibrosis is a neglected manifestation of SSc and warrants further investigation including to determine clinical outcomes and optimal therapeutic strategy.
- Subjects
SKIN diseases; DISEASE progression; SKIN; FIBROSIS; SYSTEMIC scleroderma; CONCEPTUAL structures; LONGITUDINAL method; DISEASE complications
- Publication
Rheumatology, 2023, Vol 62, pSI54
- ISSN
1462-0324
- Publication type
Article
- DOI
10.1093/rheumatology/keac363